Transgenic GroupTSE:2342 -0.93%60 Days Payable is 13.61 as of Mar. 2026, which is 13% above its 10-year median of 12.03. GuruFocus rates TSE:2342 with a GF Score™ of 60/100 and a GF Value™ of 円257.65 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 700 Biotechnology companies, Transgenic Group ranks worse than 93% on this metric.
The historical rank and industry rank for Transgenic Group's Days Payable or its related term are showing as below:
TSE:2342'
s Days Payable Range Over the Past 10 Years
Min: 2.49 Med: 12.03 Max: 28.39
Current: 14.38
During the past 13 years, Transgenic Group's highest Days Payable was 28.39. The lowest was 2.49. And the median was 12.03.
TSE:2342's Days Payable is ranked worse than 93% of 700
companies
in the Biotechnology industry
Industry Median: 112.83
vs TSE:2342: 14.38
Transgenic Group's Days Payable
declined
from Mar. 2025 (13.99) to Mar. 2026 (13.61).
It may suggest that Transgenic Groupaccelerated paying its suppliers.
Transgenic Group Days Payable Related Terms
Transgenic Group Days Payable Historical Data
* Premium members only.
The historical data trend for Transgenic Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2342 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Transgenic Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgenic Group Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgenic Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Transgenic Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Transgenic Group's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgenic Group (TSE:2342) has a Days Payable of 13.61 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Transgenic Group and its competitors. This is 13% above median its historical median of 12.03. Over the past decade, Transgenic Group's Days Payable has ranged from 2.49 to 28.39. According to the industry distribution chart, Transgenic Group ranks #651 out of 700 companies in the Biotechnology industry, placing it in the top 93%.
Is Transgenic Group's Days Payable too high?
Transgenic Group's current Days Payable of 13.61 is 13% above median its 10-year median of 12.03. Over the past 10 years, this metric has ranged from a low of 2.49 to a high of 28.39. The Biotechnology industry median Days Payable is 112.83. Transgenic Group's value of 13.61 is 87.9% below this industry median. Based on the distribution chart, Transgenic Group ranks #651 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Transgenic Group has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Transgenic Group's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgenic Group ranks #651 out of 700 companies for Days Payable. This places Transgenic Group in the lower half of its industry. The industry median Days Payable is 112.83. Transgenic Group's value of 13.61 is 87.9% below this benchmark. Historically, Transgenic Group's own Days Payable has ranged from 2.49 to 28.39 over the past decade. While the company's 10-year median is 12.03 vs. the industry median of 112.83, Transgenic Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transgenic Group's current Days Payable of 13.61 is 87.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Transgenic Group and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgenic Group's current Days Payable is 13.61, which is 13% above median its own 10-year median of 12.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgenic Group stock overvalued right now?
Based on GuruFocus' analysis, Transgenic Group (TSE:2342) is currently considered Modestly Undervalued. The stock's GF Value™ is 円257.65, compared to a current price of 円214.00 — trading 16.9% below its estimated fair value. The current Days Payable is 13.61, which is 13% above median its 10-year median of 12.03 and 87.9% below the Biotechnology industry median of 112.83. Transgenic Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Transgenic Group (TSE:2342), the current Days Payable is 13.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgenic Group (TSE:2342) Overvalued in 2026?
Based on GuruFocus' analysis, Transgenic Group stock appears to be undervalued.
The current stock price of 円214.00 is trading 16.9% below its estimated GF Value™ of 円257.65.
GuruFocus considers Transgenic Group to be Modestly Undervalued.
Key valuation signals for TSE:2342:
Days Payable: 13.61 (13% above median its 10-year median of 12.03)
GF Value™: 円257.65 vs. price of 円214.00 (16.9% below fair value)
Industry Position: 87.9% below the Biotechnology median (#651 of 700)
No single metric tells the full story. See the TSE:2342 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
60GF Score
Get the complete analysis for TSE:2342
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2342 has been successfully added to your 
